Overall, an important study with promising findings, and I'm proud to have been a member of this team! 17/ cc: Tyler Seibert MD PhD Shankar Siva Morten Hiul Suppli Pierre Blanchard, MD Albert Koong, MD PhD Amir Safavi Piet Ost Jarushka Naidoo Jahan Mohiuddin, MD Memorial Sloan Kettering Radiation Oncology

Shankar Siva puts on an audiovisual Masterpiece with impressive results, establishing a new standard of care as SABR for inoperable RCC. Bravo ! #sabr #astro23 #petermac

Steven David -late breaking abstract #ASTRO23 - investigating SANR for patients with oligoprogression in ER+ve Her2 -ve #breastcancer. Primary EFS endpoint met, and 1 in 3 patients amenable to repeat SABR, resulting in ‘real world’ mPFS of 10.1mo. 👏🏽👏🏽👏🏽🍾 congrats!!!

Congratulations Steven David 👏👏😊 huge amount of work, presented so clearly and with beautiful slides ☺️ Peter Mac Radiation Oncology Peter Mac Research Trans Tasman Radiation Oncology Group #breastcancer team #ASTRO2023

Thanks to the patients and the trial team. AVATAR presented at #ASTRO2023 #radonc Peter Mac Radiation Oncology

The COSA AM is in Melbourne this November. It's a highlight of the Australian oncology calendar, and I'm looking forward to presenting on oligometastatic breast cancer. Registrations are at bit.ly/3Mwpunk Hoping to see you there! #COSA23

Steven David @learningonco Heitor Brito #AVATAR was a standout at ASTRO this year. Kudos for the remarkable effort!

A/Prof Steven David sharing a phase 2 trial of stereotactic #radiotherapy for oligoprogressive ER positive breast #cancer #RANZCR2023

Metastatic #breastcancer at #COSA23 . A/Prof Steven David takes the stage to discuss future directions in #oligometastatic breast cancer care. Alongside A/Prof Shom Goel & Dr Stephen Luen (also from Peter Mac Cancer Centre) & Kerry Patford, breast care nurse. 👏 Steven David COSA

Off and running at this year’s #SABR2023 ⁦Peter Mac Cancer Centre⁩ ⁦Peter Mac Radiation Oncology⁩. Sold out symposium.

Piet Ost argues the case for SABR in oligometastatic #prostatecancer - a low toxicity intervention. To better select for patients who benefit most, think biomarkers of the future (genomics), and a role for SABR in mCRPC from ARTO trial #pcsm #radonc #SABR2023

The breast plenary session at #TROGASM24 continues as Emma Connolly took the stage with the latest update on the groundbreaking Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer (AVATAR): A Phase II Prospective Multicentre Trial!

Big thank you to TROG Cancer Research and my supportive supervisor Steven David Peter Mac Radiation Oncology for a fantastic opportunity to speak at this year’s ASM #TROG2024 #TROGASM24

Our phenomenal #radonc team!! A superbly productive and energising day of aspirations and strategic planning Peter Mac Radiation Oncology #thefutureisbright 😎 Peter Mac Cancer Centre Sandro Porceddu

Wonderful summary on #oligometastatic disease and #oligoprogression in #breastcancer by excellent speakers Prue Francis and Steven David Breast Cancer Trials #bct2024 Looking forward to AVATAR-2 ⚡️⚡️ Peter Mac Radiation Oncology

🚩 Sharing our latest article: Here we show that dose dense AC-T, radiotherapy & age affects long-term lymphocyte counts post adjuvant #breastcancer treatment ?implications for IO therapy nature.com/articles/s4152… 👏 Julia Dixon-Douglas Gustave Roussy Peter Mac Research The Breast Cancer Research Foundation

Congrats to Dr. Belle Sasse on this impactful study! 🎉 Collaboration between Monash Health & Peter Mac Radiation Oncology shows metastatic breast MDMs changed treatment plans in 28.1% of patients, highlighting their invaluable role in care. 👉 Read: thebreastonline.com/article/S0960-…